Shares of R1 RCM Inc. (NASDAQ:RCM – Get Free Report) have received a consensus rating of “Moderate Buy” from the thirteen research firms that are presently covering the company, Marketbeat reports. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $15.83.
RCM has been the subject of a number of analyst reports. Royal Bank of Canada restated an “outperform” rating and issued a $19.00 price target on shares of R1 RCM in a research note on Friday. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price target on shares of R1 RCM in a research note on Wednesday, April 10th. KeyCorp restated a “sector weight” rating on shares of R1 RCM in a research note on Wednesday, April 10th. Canaccord Genuity Group decreased their price target on R1 RCM from $16.00 to $15.00 and set a “buy” rating for the company in a research note on Thursday, May 9th. Finally, Citigroup upgraded R1 RCM from a “neutral” rating to a “buy” rating and set a $16.00 price target for the company in a research note on Wednesday, March 20th.
Read Our Latest Stock Analysis on R1 RCM
Institutional Trading of R1 RCM
R1 RCM Stock Up 0.5 %
Shares of R1 RCM stock opened at $12.56 on Monday. The business’s 50 day simple moving average is $12.43 and its 200 day simple moving average is $11.88. R1 RCM has a 52-week low of $8.87 and a 52-week high of $18.70. The firm has a market cap of $5.29 billion, a PE ratio of -157.00 and a beta of 0.86. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.79 and a current ratio of 1.79.
R1 RCM (NASDAQ:RCM – Get Free Report) last announced its earnings results on Wednesday, May 8th. The healthcare provider reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). R1 RCM had a negative net margin of 1.39% and a negative return on equity of 1.16%. The firm had revenue of $603.90 million during the quarter, compared to analyst estimates of $612.88 million. R1 RCM’s revenue was up 10.7% on a year-over-year basis. On average, analysts predict that R1 RCM will post -0.17 earnings per share for the current fiscal year.
R1 RCM Company Profile
R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.
Further Reading
- Five stocks we like better than R1 RCM
- High Flyers: 3 Natural Gas Stocks for March 2022
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- What does consumer price index measure?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Airline Stocks – Top Airline Stocks to Buy Now
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.